On the PCP side there was a 15% cut so 44 reps plus 1 manager were let go. They looked at overall TRx volume of Invokana and Xarelto in deciding who was cut.
My guess this was a rushed and last minute decision as Janssen has a reputation for nickel and diming their promotional spending.
Overall 2017 is not going to be pretty for Invokana when Pfizer launches its Sglt2+Januvia combo, Jardiance pushes its cardio indication and Farxiga continues its price war.